S
Setsuko K. Chambers
Researcher at University of Arizona
Publications - 158
Citations - 7181
Setsuko K. Chambers is an academic researcher from University of Arizona. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 45, co-authored 153 publications receiving 6016 citations. Previous affiliations of Setsuko K. Chambers include Yale University & University of Rochester.
Papers
More filters
Journal ArticleDOI
Radiation Therapy as Exclusive Treatment for Medically Inoperable Patients with Stage I and II Endometrioid Carcinoma of the Endometrium
David A. Fishman,Kenneth B. Roberts,Joseph T. Chambers,Ernest I. Kohorn,Peter E. Schwartz,Setsuko K. Chambers +5 more
TL;DR: This study demonstrates that exclusive radiation therapy is a well-tolerated and effective treatment for medically inoperable patients.
Journal ArticleDOI
Parametrial involvement, regardless of nodal status: A poor prognostic factor for cervical cancer
TL;DR: Involvement of the parametria, regardless of lumph node status, and adenocarcinoma histology confer a poor prognosis in high-risk patients undergoing radical hysterectomy, and Multivariate analysis showed that adenOCarcinomas histology and parametrial involvement were independent, poor prognostic indicators for disease-free interval.
Journal ArticleDOI
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
Elizabeth M. Swisher,Tanya T. Kwan,Amit M. Oza,Anna V. Tinker,Isabelle Ray-Coquard,Ana Oaknin,Robert L. Coleman,Carol Aghajanian,Gottfried E. Konecny,David M. O'Malley,Alexandra Leary,Diane Provencher,Stephen Welch,Lee-may Chen,Andrea E. Wahner Hendrickson,Ling Ma,Prafull Ghatage,R Kristeleit,Oliver Dorigo,Ashan Musafer,Scott H. Kaufmann,Julia A. Elvin,Douglas I. Lin,Setsuko K. Chambers,E. Dominy,Lan Thanh Vo,Sandra Goble,Lara Maloney,Heidi Giordano,Thomas Harding,Alexander Dobrovic,Clare L. Scott,Kevin K. Lin,Iain A. McNeish +33 more
TL;DR: In this paper, a post hoc exploratory biomarker analysis of pre-and post-platinum ARIEL2 samples, RAD51C and RAD51D mutations and high-level BRCA1 promoter methylation predict response to rucaparib.
Journal ArticleDOI
NEU protein overexpression in benign, borderline, and malignant ovarian neoplasms☆
TL;DR: A role for the NEU gene product in the physiology of benign ovarian surface epithelium and the neoplastic epithelial cells of preinvasive borderline and some invasively malignant adenocarcinomas is suggested.
Journal ArticleDOI
Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features.
TL;DR: EmGD frequently shows LOH at multiple chromosomal loci, particularly at 17p and 1p, which strongly suggests that EmGD is a noncancerous precursor lesion of UPSC, probably also of serous EIC.